References :
- Teichgräber UK, Pfitzmann R, Hofmann HA. Central venous port systems as an integral part of chemotherapy. Dtsch Arztebl Int 2011; 108(9): 147-53.
- Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008; 58(6): 323-46.
- Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Management of venous port system in oncology: a review of current evidence. Ann Oncol 2008; 19(1): 9-15.
- Gebauer B, Teichgräber UK, Hothan T, Felix R, Wagner HJ. Contrast media pressure injection using a portal catheter system--results of an in vitro study. Rofo 2005; 177(10): 1417-23. [Article in German]
- Plumb AA, Murphy G. The use of central venous catheters for intravenous contrast injection for CT examinations. Br J Radiol 2011; 84(999): 197-203.
- Ljung R, Petrini P, Lindgren AK, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81(11): 918-20.
- Weldon CB, Jaksic T, Shamberger RC. General Principle of Surgery. In: Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Elsevier; 2011. p. 386-403.
- Bairnsdale Regional Health Service. Accessing Totally Implantable Devices: Regional Health Service Nursing Practice Manual. Australia: Bairnsdale Regional Health Service; 2004. p. 1-8.
- Vascular access systems-Port-a-cath: Instructions for use. USA: Deltec; 2000. Available from: http:// www. smiths-medical. com/upload/ products/ product_ relateddocs/access/PORT-A-CATH-Access-Systems/19439_3746_01B.pdf.
- Central Venous Access devices. Nursing Standard
2000; 14(43): 45-55.
- Liang E. Portacath Insertion. Available from: http://www.sir.net.au/portacath_pi.html.
- Khaleghnejad Tabari A, Saeeda M, Rouzrokh M, Mirshemirani A. Applying totally implantable venous access devicess(TIVAD) in children: the first Iranian experience. Iranian J Blood and Cancer 2010; 2(3): 127-30.
- Rouzrokh M, Shamsian BS, Khaleghnejad Tabrari A. Totally implantable subpectoral vs subcutaneous port systems in children with malignant diseases. Arch Iranian Med 2009; 12(4): 389-94.
- Weigand K, Encke J, Meyer FJ, Hinkel UP, Munder M, Stremmel W, et al. Low levels of prothrombin time (INR) and platelets do not increase the risk of significant bleeding when placing central venous catheters. Med Klin (Munich) 2009; 104(5): 331-5.
- Carr E, Jayabose S, Stringel G, Slim M, Ozkaynak MF, Tugal O, et al. The safety of central line placement prior to treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2006; 47(7): 886-8.
- Cote CJ. Pediatric Anesthesia. In: Miller RD. Miller’s Anesthesia. Philadelphia: Elsevier, 2010. p. 2559-94.
- Shamsian BS, Kajizadi M, Rezaei N, Ghojehvand N, Azma R, Rouzrokh M, et al. Primary intrarenal neuroblastoma with hypertension and disseminated intravascular coagulation. Case Rep Oncol Med 2013; 2013: 684939.
- Shamsian BS. Oncologic Emergencies in Pediatrics Patients with Leukemia. Tehran: 34th Annual Congress of Dr Gharib.
- Patient Information: PORT -A-CATH, Implantable Venous Access Systems. Available from : http://www. smiths-medical.com.
- Clinician Information Port-A-Cath and P.A.S. Port
Implantable Access System-Pharmacia Deltec. Available from:
http://www.smiths-medical.com.
- Jett J, Digrazia J. Implantable portal access device; 2009. Available from: http://www.sh.lsuhsc.edu/policies/policy_manuals_via_ms_word/nursing/p-81.pdf.
- Lau E. Drug handbook and formulary. Toronto: :Lexicomp; 2012. p. 303-5.
- Archaya S. Thrombotic Disorders. In: Lanzkowsky P. Manual of pediatric hematology and oncology. 15th ed. Philadelphia: Elsevier; 2011. p. 419-60.
- Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Ann Oncol 2008; 19(1): 9-15.
- Guidelines for insertion and maintenace of central venous access devices in children and young people; 2002. Available from: http://www.gain-ni.org/images/
Uploads/ Guidelines/Gain-CVAD-2012.pdf.
- Koh A, Pizzo PA. Infectious complications in pediatric cancer patients. In: Pizzo, PA. Principles and Practice of Pediatric Oncology. Philadelphia: Elsevier; 2011. p. 1190-1235.
- Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1): 1-45.
- Welker D. Troubleshooting Vascular Access Devices; 2004. Available from: http://www.smiths-medical.com.
- West Gippsland Healthcare Group. Implantable ports- care and maintenance of venous ports. Nursing Procedure 2002; 32(6): 1-5.
|
|
|
|
|
Sci J Iran Blood Transfus Organ 2015; 12(1): 85-99
|
|
|
|
|
|
The clinical application of port A Cath in the
hematology-oncology patients
Arzanian M.T.1, Shamsian B.Sh.1, Eshghi P.1, Kajiyazdi M.1, Alavi S.1, Nazari Sh.1,
Goudarzipour K.1
1Pediatric Congenital Hematologic Disorders Research Center, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Background and Objectives
The use of vascular access devices (VADs) is an integral aspect of health care for neonates, children, and adults and has moved beyond the acute care setting to chronic, long-term care. VADs have a paramount role throughout the management of the oncology patient, as they are needed in the initial phases for surgery or chemotherapy, in the advanced stages for chronic treatment, and in the last stages for palliative measures. In patients with cancer, chemotherapeutic drugs can damage the wall of peripheral veins thereby rapidly putting an end to the peripheral access. Central venous lines (CVLs) were first described by Dudrick in 1968. In 1973, the first long-term central venous catheter (CVC) was used for parenteral nutrition. In 1979, the Hickman catheter, a long-term venous access device, was used for chemotherapy for the first time. The introduction of totally implantable port systems started in the early 1980s. In this article, we will review the use of port A Cath and its role in hematology-oncology patients based on the literature review.
Materials and Methods
This article was provided based of review of many recent anf up-to-date articles in field of port A Cath uding and its role in hematology-oncology patients.
Results
Evaluation these articles showed the essential role of port A Cath and the best ways to deal with the possible complications.
Conclusions
Review of articles revealed the essential role of port A Cath in hematology-oncology patients. Also it is necessary to be careful about using and care of port A Cath.
Key words: Port-A-Cath, chemotherapy, patients
Received: 19 Nov 2013
Accepted: 4 Aug 2014
Correspondence: Shamsian B.Sh., MD. Pediatric Hematologist Oncologist of Pediatric Congenital Hematologic Disorders Research Center, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences.
P.O.Box: 15468-15514,Tehran, Iran. Tel: (+9821) 22048430; Fax: (+9821) 22220254
E-mail:
shahinshamsian@gmail.com